Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Globe Newswire•13/08/2026•07:30 ET
0
Whiz Insights
‒ Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million ‒
‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒
Get started
Create a free account to read the full story.